

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Find a Doctor](#) [Find a Clinical Trial](#) [Find a Treatment](#)
[Consult with a Cancer Center](#) [Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA
MSK has a long and proud history of cancer drug discovery and a legacy of many effective therapies in use today. In recent years, as the processes associated with drug development have become increasingly more complicated and expensive, we've recognized the need to accelerate and improve the procedures required to move investigations from the basic discovery phase to human trials.



Center for Experimental Therapeutics Director David Scheinberg

In 2002, the generous support of William H. and Alice Goodwin and their Commonwealth Foundation for Cancer Research enabled us to establish the Center for Experimental

Therapeutics with the goal of enhancing and coordinating drug development activities at MSK. The center currently gives broad support to numerous scientific innovations that show the potential to become therapeutic breakthroughs, including both financial and administrative help.

Our researchers receive funding through Center for Experimental Therapeutics administered grants and have access to laboratory expertise and services provided by core facilities, as well as advisory support from experts in intellectual property, licensing, and patents. In addition, the center offers a number of educational opportunities such as retreats, symposia, and research-in-progress meetings to cultivate intellectual synergies.

The Center for Experimental Therapeutics has created a dynamic research environment at MSK, and a cohesive and highly productive community of scientists. It has enhanced our ability to pursue drug development while ensuring that every promising discovery made in our laboratories and clinics will reach its full potential for benefiting people with cancer.

New Alliances

An additional and related enterprise has been created to further enhance the ETC's drug development program. The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) is a unique partnership among Weill Cornell Medical College, Memorial Sloan Kettering and Rockefeller University. Tri-I TDI has entered into an initial partnership with Takeda Pharmaceuticals to assist academic investigators at the three institutions to develop small molecule therapeutic agents and molecular probes.

[Learn more about the partnership »](#)
